In R/R DLBCL patients of auto-SCT ineligible, although the Pola-BR group had higher rates of grade 3–4 neutropenia, anemia, and thrombocytopenia (but similar rates of grade 3–4 infections), Pola combined with BR (Pola-BR) resulted in a significantly improved CR rate (40.0% v 17.5%), PFS (median, 9.5 v 3.7 months, HR, 0.36) and OS (median, 12.4 v 4.7 months, HR, 0.42) compared with BR alone [29]. The gene discussed is POLA1; the disease is diffuse large B-cell lymphoma.